Woodline Partners LP Acquires 88,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Woodline Partners LP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 33.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 352,680 shares of the company's stock after acquiring an additional 88,424 shares during the period. Woodline Partners LP owned about 0.69% of Spyre Therapeutics worth $8,210,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in SYRE. Huntington National Bank acquired a new stake in shares of Spyre Therapeutics during the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Spyre Therapeutics during the 4th quarter worth approximately $46,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Spyre Therapeutics during the 4th quarter worth approximately $182,000. Tower Research Capital LLC TRC boosted its position in shares of Spyre Therapeutics by 1,548.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company's stock worth $200,000 after acquiring an additional 8,054 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in shares of Spyre Therapeutics by 38.4% during the 4th quarter. Arizona State Retirement System now owns 10,115 shares of the company's stock worth $235,000 after acquiring an additional 2,805 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on SYRE. Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 8th. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partners initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 target price on the stock. Wolfe Research initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 target price on the stock. Finally, Wedbush restated an "outperform" rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, May 5th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Spyre Therapeutics has an average rating of "Buy" and an average price target of $53.40.

Spyre Therapeutics Stock Up 0.8%

Shares of SYRE stock traded up $0.12 during trading hours on Wednesday, hitting $15.11. 55,824 shares of the company's stock traded hands, compared to its average volume of 610,666. The stock's 50 day simple moving average is $14.46 and its 200 day simple moving average is $20.36. The stock has a market cap of $910.47 million, a PE ratio of -2.02 and a beta of 2.78. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.26.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.02. As a group, equities research analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).